Thursday, April 30, 2020

Medical Holography Market Poised to Expand at a Robust Pace by 2028

The global medical holography market features an extremely competitive market landscape with numerous market players focusing on the development of new products, reports Transparency Market Research. Key companies operating in the market comprise RealView Imaging Ltd., Lyncée Tec SA, Integraf LLC, EchoPixel, Inc., HoloTech Switzerland AG, Holoxica Ltd., EON Reality Inc., and Koninklijke Philips N.V. These companies are focusing on strategic mergers and acquisitions and enhancing their production capacities to meet the growing demand. The intense competition between these players is mainly driven by new innovations in the medical holography market. 

Request For Covid19 Impact Analysis on Medical Holography Market -

As per TMR analysts, the global medical holography market is expected to usher at an astounding CAGR of 30% during the forecast period which is 2018 to 2026. Growing at this pace, the market is expected to rise from its initial value of US$ 240.0 Mn to reach the mark of US$ 3500.0 Mn by 2026. 

On the basis of product, the global medical holography market is segmented into holography microscope, holographic display, holography software, and holographic prints. Out of these, the holographic display segment is expected to hold dominance over the market owing to recent innovations in holographic display and wide use in displaying holographic images. 

On the geographical front, the global medical holography market is divided into Europe, North America, Latin America, Asia Pacific, and Middle east and Africa. Of these, Europe and North America have emerged as leaders in the market owing to the presence of large patient base and high incidence of chronic diseases. 

Request for Brochure of Report -

High Demand from Academic Centers to Boost Growth 

The medical holography technique is booming incessantly in the light of recent technological developments. It finds extensive usage in academic centers to get a better understanding of the anatomy of diseases. Moreover, there is a high demand for holography imaging from healthcare and research industries. These factors have impacted the global medical holography market positively, thus stimulating growth. 
Furthermore, factors such as rise in the number of chronic diseases and growing geriatric population are perceived to cause a spur in the market’s growth. In addition to this, innovations in the design of imaging equipment such as introduction of 4D imaging techniques may present significant growth opportunities for the market’s growth. 
Additionally, improvements in hologram recording techniques have strengthened the growth ground of the global medical holography market. Moreover, rise in the funding and investment for the development of new medical holographic products has propelled the market’s growth.

Request for Custom Research -
However, along with the numerous drivers, there are a few restraints that may cause a downfall in the global medical holography market. Factors such as high initial investment and processing costs may cause an impediment in the market’s growth. Nonetheless, the benefits offered by medical holography technology over the conventional techniques may reduce the effects of the restraints. Moreover, focus on new product developments may create numerous growth opportunities for the market. 

Advancements in Technology to Create New Avenues 
Microsoft has recently developed “Hololens 2”, a virtual reality technology featuring holograms. It offers an excellent mixed reality experience with the scalability of cloud and AI services. With the help of Hololens 2 you can see the intricate details of a 3D image with a high resolution. Moreover, it offers excellent ease of use with its dial-in fit system. Such technological developments have presented lucrative growth opportunities for the global medical holography market.

More Trending Reports by Transparency Market Research –  
Particle Therapy Market –

Psoriasis Treatment Market –
Posted by at No comments:

Us Population Health Management Solutions Market Foreseen to Grow Exponentially by 2023

The market for U.S. population health management solutions is expected to see various strategies that are being adopted by market players to keep up with technological elevations. In a report that is being published by Transparency Market Research (TMR), most of the market players could constantly innovate in the market through means of the development of novel software and services. Apart from this, improvisation of existing offerings to keep up with the technological advancement in the market is also another factor that is driving the market. This could result in helping market players secure a totally reliable position in the industry. Some of the prominent market players that are involved with population health management solutions in the U.S. are Health Catalyst, Healthagen, and IBM.

In accordance with the statistics of TMR, the U.S. population health management solutions market could earn revenue of around US$ 45.7 bn by the year 2023 at a CAGR of 23.9% over the forecast timeframe that extends from the year 2015 to 2023. By the type of source, the services market is expected to achieve a higher growth rate between the year 2015 and 2023.

Request For Covid19 Impact Analysis on Us Population Health Management Solutions Market –

Government Policies to Fuel Market Demand
The demand pertaining to the U.S. population health management solutions market is expected to gain momentum at the back of the robust enforcement of beneficial healthcare acts in the US. The demand for population health management solutions in the U.S. are expected to be encouraged by the soaring prevalence of chronic ailments in the US. Apart from this, the expanding size of the base of geriatric population in the country is likely to result in the augmented demand of the market. The regional market of North America is likely to be a popular choice for population health management solutions, taking into consideration the increase in total spending on healthcare in the last few years. This would offer an impetus to the said market.

There has been a growing demand for the implementation of effective and efficient population health management solutions owing to the alarming rise in the expenses related to healthcare. The U.S. government could, however, resort to the precise tracking of the health of the population. There could be a need for population health management solutions for the purpose of accomplishing the requirement to come up with healthcare enterprises that are patient-centric and organize an efficient population health management practices. As such, providers of healthcare are expected to incorporate population health management solutions at an increased rate.

Request for Brochure of Report -

Expanding Geriatric Population to Impact Market Positively  
The market for population health management market in the U.S. has been classified on the basis of mode of operation, end user, and type of source. On the basis of source, population health management software and the population health management services are the two of the significant market categories of the population health management market in the U.S. Of the two the classifications, the category of population health management services is very likely to secure the foremost position in the said market. The fast advancement of this segment can be linked to the increasing requirement for high productivity and cost effectiveness that is being given by the population health management services. 

Request for Custom Research -

On the basis of end user, the market for U.S. population health management has been classified into diagnostic and imaging centers, medical device organizations, government insurance providers, research institutes, employers, pharmaceutical companies, private insurance providers, and healthcare providers. Of all of these categories, healthcare providers are poised for substantial growth during the period of forecast.

Increased expenditure on healthcare, private investments, and soaring consciousness regarding health in the domain of population health management solutions in the U.S. are attributed with the distinct progress of this market category. Furthermore, the increasing elderly population base across the country is also fuelling the improvisation and implementation of population health management solutions by the healthcare providers.

More Trending Reports by Transparency Market Research –  
Culture Media Market –

Sepsis Therapeutics Market –
Posted by at No comments:

Diabetic Foot Ulcers Treatment Market Estimated to Flourish by 2027

Diabetic Foot Ulcers Treatment Market: Introduction
According to a new market report published by Transparency Market Research, the global diabetic foot ulcers treatment market was valued at US$ 5 Bn in 2018 and is estimated to reach a market value of ~US$ 9.6  Bn by 2027, growing at a CAGR of 7.5% from 2019 to 2027. Diabetic foot ulcers are a major complication arising out of diabetes mellitus. Various factors are responsible for this type of chronic wound, such as peripheral neuropathy, and peripheral artery diseases. Chronic wounds have created a significant socioeconomic impact. Chronic wounds generally take longer time to heal and require advanced wound care therapies. Diabetic ulcers are becoming more common due to increased incidence of both type I and maturity-onset diabetes in the developed economies across the world. Thus, increase in prevalence of diabetic foot ulcer is expected to drive the diabetic foot ulcers treatment market in the next few years.

Request For Covid19 Impact Analysis on Diabetic Foot Ulcers Treatment Market –

The global diabetic foot ulcers treatment market was valued at US$ 5.0 Bn in 2018 and is anticipated to reach US$ 9.6 Bn by 2027, expanding at a CAGR of 7.5% from 2019 to 2027. North America, Europe, and Asia Pacific were major markets for diabetic foot ulcers treatment in 2018. Global diabetic foot ulcers treatment market in Asia Pacific is projected to expand at a high CAGR of 8.0% during the forecast period.

Rise in Prevalence of Chronic Disease to Drive Market
High growth rate of the diabetic foot ulcers treatment market during the forecast period can be attributed to rise in prevalence of chronic diseases such as diabetes, cancer, HIV, and other diseases leading to increased risk of diabetic foot ulcers among the diabetic population; and longer hospital stays due to treatment of these diseases resulting in risk of hospital-acquired pressure ulcers and medical devices-acquired pressure ulcers. A constant increase in geriatric population among developed and developing countries has been observed, along with rise in obesity and peripheral artery diseases, which leads to decreased mobility and increased risk of acquiring chronic ulcers

Request for Brochure of Report -

Wound Care Dressings to be Preferred Treatment Type
In terms of treatment type, the diabetic foot ulcers treatment market has been segmented into wound care dressings, wound care devices, active therapies, and others. The wound care dressings segment is anticipated to hold major share of the market during the forecast period. Increase in incidence of peripheral vascular as well sugar related diseases, and other chronic diseases leading to rising risk of hospital acquired pressure ulcers is expected to drive the segment during the forecast period

Grade 1 Ulcers to Dominate Global Market
In term of grade, the diabetic foot ulcers treatment market has been segmented into grade 1, grade 2, grade 3, grade 4, and grade 5. The grade 1 segment is expected to dominate the market during the forecast period.

Request for Custom Research -

Rise in Prevalence of Neuropathic Ulcers to Fuel Market Growth
In terms of type of ulcer, the diabetic foot ulcers treatment market has been segmented into neuropathic ulcers and ischemic ulcers. The neuropathic ulcers segment is expected to dominate the market from 2019 to 2027.

Hospital Inpatient Settings to be Key End User
In terms of end user, the diabetic foot ulcers treatment market has been categorized into hospital inpatient settings, hospital outpatient settings, community health centers, and home healthcare. In terms of end user, the hospital inpatient settings segment is expected to drive the market. Reasons for growth of the segment include the demand for acute care for the treatment of chronic wounds and rise in incidence of diabetic foot ulcers and pressure ulcers around the world. However, lack of hospital inpatient facilities and availability of limited resources have led to emergence of community health centers and home healthcare facilities for wound care. This is expected to drive community health centers and home healthcare segments during the forecast period.

Growth Strategies of Key Players: Diabetic Foot Ulcers Treatment Market
Major players having presence in the global diabetic foot ulcers treatment market include 3M Healthcare, Smith & Nephew Plc., Acelity L.P. Inc., ConvaTec, Inc., Molnlycke Health Care AB, Coloplast A/S, Medtronic Plc, B. Braun Melsungen AG, Organogenesis, Inc., Medline Industries, Inc., and BSN Medical GMBH. These companies engage in research & development activities to develop novel products in order to expand product offerings and customer base

More Trending Reports by Transparency Market Research –  
Brain Tumor Diagnosis and Treatments Market –

Sterilization Services Market –
Posted by at No comments:

Interventional Cardiology Devices Market to Witness an Outstanding Growth by 2022

According to the report by Transparency Market Research (TMR), the global interventional cardiology devices market has highly consolidated landscape. Some of the key players operating in the global interventional cardiology devices market are Boston Scientific, Medtronic, Abbott Vascular, St Jude Medical, and Volcano Corporation. Among these, the three players including Boston Scientific, Medtronic, and Abbott Vascular are accounting for the share of 66.9%.

According to a report by Transparency Market Research (TMR), the global interventional cardiology devices market is expected to expand with a CAGR of 2.9% from 2014 to 2022, to attain the value of US$11.16 bn by the end of 2022 from US$9.36 bn in the year 2016. On the basis of product type, the stents segment is dominating the global market for interventional cardiology devices and expected to continue its dominance over the forecast period by collecting revenue of about US$6.89 bn until the end of 2022. On the basis of region, North America is dominating the global market for interventional cardiology devices and expected to continue its dominance by collecting US$4.04 bn by the end of 2022. This growth is attributable to the high adoption of the stents.

Request For Covid19 Impact Analysis on Interventional Cardiology Devices Market –

Technological Advancements to Fuel Adoption  
Increasing geriatric population and obesity are leading to an increase in the prevalence of cardiovascular disease. Additionally, changing lifestyle that is characterized by smoking, high alcohol consumption, and lack of physical exercise have increased the prevalence of coronary artery diseases. The interventional cardiology devices help cardiologists to perform the procedures quickly, without letting the procedure to get complicated. Rising demand for the safe and advanced technology is fuelling growth of the global interventional cardiology devices market.

Request for Brochure of Report -

The treatment of cardiovascular disorders has changed from past few years owing to introduction of new drugs and advanced therapies which helps to live better and longer lives. Advancement in research and development (R&Ds) activities to develop novel drugs and devices plays a key role in the growth of the market. The continuous technological advancement in the interventional cardiology devices market is boosting adoption which is likely to fuel growth of the global interventional cardiology devices market.  

Request for Custom Research -

Government Initiatives for Improving Knowledge to Create Opportunities
Despite these growth opportunities, high manufacturing cost of these devices is a major factor hampering growth of the global interventional cardiology devices market. Additionally, price cut by the local players is pressurizing global players to reduce their prices which is crimping growth of the global interventional cardiology devices market. Nevertheless, numerous initiatives by the governments to increase awareness level about cardiovascular diseases and importance of regular medical checkup camps are creating lucrative opportunities for the growth of market.

More Trending Reports by Transparency Market Research –  
Medical Electrode Market –

Varicose Vein Treatment Market –
Posted by at No comments:

North America Endoscopy Devices Market is Expected to Expand at an Impressive Rate by 2022

The global endoscopy equipment market is estimated to witness notable growth in the coming years as Transparency Market Research reports. This is due to the increasing number of gastrointestinal diseases as well as cancer. The competitive landscape of the global endoscopy equipment market is seen to be fragmented due to the presence of a large number of players. Major players are putting more focus on the development of new products and their product launching in order to stay in the market and maintain a dominant place.
Some of the prominent players of the global endoscopy equipment market are Fujifilm Holdings Corporation, Stryker Corporation, Karl Storz GmbH & Co., Smith & Nephew Plc, Karl Storz GmbH & Co., Boston Scientific Corporation, and Arthrex Inc. Major vendors are making efforts to develop new products and accelerate the overall growth of the market during the forecast period. Players are also investing more funds into research and development in order to produce better and unique results so as to improve their brand quality and give tough competition to the others.

Request For Covid19 Impact Analysis on North America Endoscopy Devices Market –

As per the TMR reports, the global endoscopy equipment market is prognosticated to reach a valuation of US$33.5 bn by 2022. The market is presumed to exhibit a promising CAGR of 4.0% within the forecast period of 2017 to 2022. As per the classification by application, the endoscopy equipment market is seen to be dominated by the gastroenterology segment owing to the increase in popularity of gastric problems all around the globe.
As per the geographical segmentation, the market is projected to be dominated by North America with an expected rise of revenue from US$9.9 bn in 2017 to US$12.3 bn by the end of 2022.

Request for Brochure of Report -

Increasing Number of Gastroenterological Diseases to Boost Market Growth
The surge in the use of endoscopic equipment for diagnosis of all kinds of gastroenterological disorders is also expected to boost the market at a global level. Another factor expected to boost the global market for endoscopy equipment is the rising investments in healthcare and medical sector for their enhancement is among the key driver to boost the overall market growth. Both the government and non-government agencies are putting efforts to set up better healthcare infrastructures in order to suffice to the medical needs of people.
Developing countries like that of New Zealand, Australia, India, China, and Japan are also presumed to increase the revenue generation of the endoscopy equipment market during the forecast period by creating better infrastructure and medical facilities in terms of treatment. The emergence and popularity of ultra-modern healthcare facilities are also creating lucrative opportunities for the overall market for endoscopy equipment.

Request for Custom Research -

High Cost of Treatment of Endoscopy to Cause Hindrance to Market Growth
One factor that may act as a hindrance to the overall growth of the market is the high treatment cost of gastroenterology and their medication as well. The high cost of treatment may make customers to think twice before opting for such treatment. Apart from that, the emerging market for ayurvedic medicines and their guaranteed no side-effect propaganda may divert patients from opting for endoscopic treatment and instead acquire natural remedies in order to cure themselves. Due to this shift, the market for endoscopy equipment may also face loss in the years to come.

More Trending Reports by Transparency Market Research –  
Insulin Delivery Devices Market –


Varicose Vein Treatment Market –
Posted by at No comments:

Thyroid Gland Disorders Treatment Market to Witness Widespread Expansion by 2025

The global thyroid gland disorder treatment market represents a highly competitive and fragmented landscape. This is mainly due to the presence of numerous small and large players in the market, says Transparency Market Research. 

Some of prominent players operating in the global thyroid gland disorder marker are Abbott, Pfizer, GlaxoSmithKline, Mylan N.V., and Amgen. These players are relying on several strategies such as partnership agreements, regional expansions, brand awareness activities, and increase product profiliration in order to gain a competitive edge in the market.  In addition, increasing FDA approval of novel drug patent for the treatment of thyroid gland disorder treatment market is expected to fuel rivalry among players in the coming years.

Request For Covid19 Impact Analysis on Thyroid Gland Disorders Treatment Market –

In june 2018,  Hutchison China MediTech Limited, a key players in the global throid gland disorder treatment market has  initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine. Once developed and successfully tested the drug is expected to treat tumors and biliary tract cancer efficiently. This is expected to fuel tyroid gland disorder market in the coming years.

In the same year, another player called AmpliPhi Biosciences Corporation presented a AB-PA01 Bacteriophage Therap. As per the company it is helpful in treating patient with cystic fibrosis.
According to TMR, the global thyroid gland disorders treatment market was noted at  a valuation of US$1,954.7 mn in 2016. The market is expected to rise at a steady 3.3% CAGR from 2017 to 2025. Rising at this CAGR, the global thyroid gland disorder treatment market is expected to hit a valuation of US$2,609.9 mn by 2025.

Planning To Lay Down Future Strategy? Request Brochure Of Thyroid Gland Disorders Treatment Market

On the basis of geography, North America is anticipated to dominate the global thyroid gland disorder treatment market during the forecast period. This can be attributed by the fact higher investments in research and development of novel drugs and equipment for treatment of chronic disorders. Along with this, early adoption of advanced healthcare technologies, rising awareness and increasing geriatric populations are some of the predominant factors expected to drive the global thyroid gland disorder treatment market in the coming years. Based on disorder, the Hypothyroidism segment  is expected to lead the global throid gland disorder treatment market in the forecast period.

Side Effects of Thyroid Gland Disorder Treatment Drugs to Impede Growth
The global thyroid gland disorder treatment market is anticipated to garner a stready growth during the forecast period. Key factor contributing the growth of thyroid gland disorder treatment market include  market include increasing prevalence of thyroid gland disorder, surge in geriatric people, rise in awareness programs by private and public body.

However, side effects of thyroid gland disorder treatment drugs, habit forming nature and stringent government regulations regarding the sales of medicines are some of the factors expected to hamper growth in the global thyroid gland disorder treatment market. In addition to this asymptomatic nature of thyroid gland disorder is one factor impeding growth in the thyroid gland disorder treatment market. This is because several thyroid gland disorder cases left untreated owing to poor diagnostic.

To Obtain All-Inclusive Information On Forecast Analysis Of Thyroid Gland Disorders Treatment Market , Request A Discount

Unprecedented Rise in Alcohol and Tobacco Consumptions to Drive Growth
Nevertheless, increasing cases of iodine deficiency across the globe is a strong factor expected to propel the growth in the global thyroid gland disorder treatment market.
Moreover, rise in alcohol and tobacco consumption also leads the thyroid disorders.  This is because they contain thiocyanate, a compound responsible to degrade thyroid functioning. This is also expected to open several opportunities for growth of the global thyroid gland disorder treatment market.

More Trending Reports by Transparency Market Research –  
E. coli Testing Market -

Osmometers Market –
Posted by at No comments:

Diabetes Devices Market Set for Rapid Growth and Trend, by 2025

As per the research conducted by Transparency Market Research, the diabetes devices market has been noted to have a consolidated vendor landscape globally. F. Hoffmann-La Roche Ltd. Medtronic plc, Sanofi S.A., Eli Lilly and Company, and Novo Nordisk A/S, are a few of the main players in the diabetes devices market globally and the main reason behind their upper hand on this market is the variety they offer in their products.

Most of these players are now focusing on entering in the developing markets and make use of the growth prospects available there because of economic development. However, manufacturing of basic and cheaply priced diabetes devices will be their main plan. One of the main plans and areas of focus for the manufacturers will be expanding geographically  by merging with the other players, as well as partnerships for their benefits.

Request For Covid19 Impact Analysis on Diabetes Devices Market –

As per the reports of Transparency Market Research, the diabetes devices market is predicted to account for a total of US$66,053.1 mn by 2025, whereas in the year 2016 it was accounted for a total of US$37220.8 mn globally thereby growing at a CAGR of 6.7%. Although there are many items that help in managing diabetes, glucose monitoring devices and the different items that fall under it are predicted to lead the diabetes devices market globally. In terms of the income generated, the glucose meters segment accounted for a total of 59.1% of the total income generated in the year 2016 globally. On the basis of geography, North America is the dominating market because of the existence of advanced as well as up to date healthcare systems.

Request for Brochure of Report -

Increasing Stress and Consumption of Alcohol Behind High Incidences of Diabetes 
Primarily, the demand for global diabetes devices market is carried forward by the growth in the number of patients diagnosed with diabetes throughout the globe. A few major reasons behind the growth in the occurrence of diabetes among patients is the stress people take, consuming alcohol in large quantities, unhealthy food consumption, as well as because of lifestyle that does not consist of much physical activities. In the last few years, the growth in the number of patients suffering from diabetes has boosted the requirement for diabetes devices.

Request for Custom Research -

New Novel Insulin Delivery Devices to Drive Demand
Due to the existence of devices like testing strips, continuous monitoring devices, lancets, self-monitoring blood glucose metres, that are cost effective as well, have a healthy impact on the market in general. Plus, the growth and awareness regarding managing diabetes is expected to bolster the diabetes devices market. Because of the entrants of new products in the market, the diabetes devices market is said to have been further boosted. Like for example, the new novel insulin delivery device is predicted to increase the requirements for diabetes devices for home disease management.

Improvement in Home Monitoring Devices to Aid Growth
Improvement in home monitoring devices are also anticipated to boost the demand for usage at homes. Along with this, the designing as well as the ease of using the devices, is considered to be an important factor too that is boosting the demand of diabetes devices for use at home. The players of this market are making devices that are very safe as well as productive, which in turn is causing the demands of the diabetes devices to rise.

More Trending Reports by Transparency Market Research –  
Sinus Dilation Devices Market –

Hemostasis Valves Market –
Posted by at No comments:

Smart Insulin Pens Market to Set Phenomenal Growth by 2027

Transparency Market Research (TMR) has published a new report titled, “Smart Insulin Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global smart insulin pens market was valued at US$ 29.2 Mn in 2018. It is projected expand at a CAGR of 10.3% from 2019 to 2027. Increase in the prevalence of diabetes, rise in awareness about chronic diseases, such as diabetes, and surge in adoption of connected medical devices are anticipated to augment the global market between 2019 and 2027.

Smart insulin pens are used to deliver insulin for the treatment of type 1 and type 2 diabetes. Smart insulin pens have additional features such as memory function, time and dose recorder, and data transfer. Rise in prevalence of both type of diabetes in children and adults, due to obesity and changing lifestyle and dietary habits, is a key factor that is anticipated to drive the global market for smart insulin pens. Additionally, technological advancements and integration of glucose monitoring and therapeutics for better diabetes management are likely to propel the global smart insulin pens market. However, availability of alternatives for insulin delivery is anticipated to restrain the global market.

Request For Covid19 Impact Analysis on Smart Insulin Pens Market –

The report offers detailed segmentation of the global smart insulin pens market based on product, connectivity type, application, and distribution channel. The market has also been segmented based on region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Adoption of technological advancements and increase in prevalence of diabetes are likely to drive the global smart insulin pens market.

Adaptors for conventional pens segment to account for leading share, while smart insulin pens segment expand significantly
In terms of product, the adaptors for conventional pens segment accounted for a leading share of the global market in 2018, and the trend is anticipated to continue during the forecast period. Increase in prevalence of diabetes in people of all ages across the globe is projected to boost the segment during the forecast period. Expansion of the smart insulin pens segment is attributed to technological advancements such as memory function and accurate dose administration.

Request for Brochure of Report -

Technological advancements in smart insulin pen to propel market
Emerging technologies in smart insulin pens are projected to boost the global smart insulin pens market during the forecast period. iSenz is an adaptor for smart insulin pens that possess a feature to detect the insulin level, by scanning. It provides the correct angles for injections in order to optimize the injection sites for diabetes. Easylog is an adaptor for insulin pens connected via the internet. This product provides the right dose and offers better comfort to the patient for the treatment of chronic diseases such as diabetes. InsulCheck, is cap for insulin pens that contains a sensor to track pen usage and temperature.

North America to be highly lucrative smart insulin pens market
North America has a large number of smart insulin pens approved for the treatment of diabetes. In the U.S., significant increase in the prevalence of diabetes is likely to propel the region’s leading share of the global market during the forecast period. Additionally, product launches and approval for smart insulin pens are anticipated to drive the market in the region.

Request for Custom Research -

Product launches by key players and patent approvals to boost market
The report also provides profiles of leading players operating in the global smart insulin pens market. These include Novo Nordisk A/S, Sanofi (sanofi-aventis US LLC), Eli Lilly and Company, Companion Medical, Emperra GmbH E-Health Technologies, Diabnext, Jiangsu Delfu medical device Co.,Ltd, BERLIN-CHEMIE, DIAMESCO CO., Ltd., and Patients Pending Ltd (Bigfoot Biomedical Inc.). In July 2018, Companion Medical, a provider of advanced technological products for diabetes, received approval from Food and Drug Administration for InPen in the U.S. This product approval enabled the company to strengthen its digital diabetes products portfolio in the U.S. In March 2018, sanofi-aventis U.S. LLC received approval from U. S. Food and Drug Administration for Toujeo Max SoloStar. This product approval enabled the company to strengthen its product portfolio.

More Trending Reports by Transparency Market Research –  
In-vitro Colorectal Cancer Screening Tests Market –

Hemostasis Valves Market –
Posted by at No comments:

Parkinson’s Disease Therapeutics Market Outlook, Trend, Growth and Share Estimation Analysis

The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research (TMR) (. The report states that high prevalence of Parkinson’s disease, rise in geriatric population across the globe, increase in funding for clinical research and grants, etc. are expected to spur the growth of the Parkinson’s disease therapeutic drugs during the forecast period, i.e. 2017 to 2025.
North America and Europe are projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. Europe is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2025, which can be ascribed to the high prevalence and rise in incidence rate of Parkinson’s disease in the developed countries in the region such as Germany, France, the U.K., and Italy, promising product pipeline, and various initiatives undertaken by the government and non-profit organizations to promote awareness regarding the disease. The Parkinson’s disease therapeutics market in Europe is expected to witness the highest CAGR of more than 11.0% from 2017-2025.
Request For Covid19 Impact Analysis on Parkinson’s Disease Therapeutics Market –
High prevalence and rise in incidence rate of Parkinson’s disease to fuel the global market
Parkinson’s disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson’s disease is not known. It is largely prevalent among the geriatric population. Classifying by gender, men are one-and-half times more affected by the disease than women. According to the Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by Parkinson’s disease and around 1 million Americans are living with it. However, the exact number of patients suffering from Parkinson’s disease is known due to incompleteness and inconsistency in the prevalent studies and underdiagnosed cases.
According to the Global Burden of Disease Study, it is estimated that around 13 million people will be affected by Parkinson’s disease worldwide by the year 2040. China has the world’s largest population affected with Parkinson’s disease, which is an estimated 2.5 million people, and the number is likely to become double by the end of 2030, accounting for half of the world’s population suffering from the disease. The rapidly growing geriatric population, coupled with high prevalence and increasing incidence rate of Parkinson’s disease in the developed countries, is projected to a key driving factor of the Parkinson’s disease therapeutics market during the forecast period.
Request for Brochure of Report -
Levodopa combination drugs to be an attractive product segment
The report offers detailed segmentation of the global Parkinson’s disease therapeutics market based on drug class, route of administration, and distribution channel. Among drug classes, the levodopa combination drugs segment is poised to account for the leading share of the global market during the forecast period from 2017 to 2025. Levodopa combination therapy is considered a highly-effective treatment for the motor symptoms associated with Parkinson’s disease and is commonly recommended by physicians across the globe. Carbidopa and levodopa combination therapy is commonly used for management of motor fluctuations in Parkinson’s disease.
The recent approval by the United States FDA and launch of Duopa in 2015 by AbbVie Inc. had significantly promoted levodopa combination drugs in 2016. Also, the anticipated launch of pipeline study of CVT-301 by Acorda Therapeutics, Inc. and ND0612 from Mitsubishi Tanabe by the end of 2019 is estimated to propel the segment’s growth during the forecast period

Request for Custom Research -

Oral route of administration, followed by intestinal infusion segment, dominates the market
In terms of route of administration, the oral route is projected to dominate the global Parkinson’s disease therapeutics market during the forecast period and is estimated to expand at a CAGR of more than 7.5% from 2017-2025. More than 70% of the drugs available for treatment of Parkinson’s disease are in the tablet and capsule form. Some of the drugs are orally disintegrated. However, the estimated launch of sublingual film by SUNOVION and inhaled formulation by Acorda Therapeutics, Inc. during the forecast period is likely to gain market exceeding 15% by the end of 2025. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson’s disease are estimated to limit the growth of the oral route of administration segment by the end of 2025.

Retail pharmacy, followed by hospital pharmacy segment, dominates the market
Among distribution channels, the retail pharmacy segment is projected to hold the dominant share of the global Parkinson’s disease therapeutics market during the forecast period and is likely to expand at CAGR of more than 11% from 2017 to 2025. Easy availability of Parkinson’s therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The hospital pharmacy segment is the second leading shareholder of the global Parkinson’s disease therapeutics market. However, the segment is likely to lose its market share by the end of 2025. Intestinal infusion drugs and subcutaneously administered drugs, and certain patented drugs, to an extent, have contributed to the key market share of the hospital pharmacy segment in 2016. The online pharmacy segment is poised to grow at as significant CAGR of more than 12% during the forecast period.

Huge incremental opportunity in Europe
In terms of value, Europe dominated the global Parkinson’s disease therapeutics market in 2016. The region is estimated to gain market share by the end of 2025. The dominance of Europe can be primarily attributed to the high prevalence of Parkinson’s disease in the region, availability of and high adoption of levodopa combination drugs, and high clinical R&D budget to address the unmet needs in Parkinson’s disease. According to the European Parkinson’s Disease Association, around 1.2 million people in European Union are affected with Parkinson’s disease. In Germany, around 260,000 people; in Italy, 150,000 people; and in the U.K., around 120,000 people are affected by the disease. The highest incidence rate of Parkinson’s disease is observed in France with around 36-49 cases per 100,000 people.

The Parkinson’s disease therapeutics market in Europe is estimated to grow at the highest CAGR of more than 11% during the forecast period. North America is the second leading market for Parkinson’s disease therapeutics. Rapid growth in the aging population of the U.S., rise in awareness regarding Parkinson’s disease, and new product approvals and launches in the region have contributed to the dominant share of the region. Moreover, high clinical R&D budget by the governments, private players, and non-profit organizations are estimated to fuel the expansion of the Parkinson’s disease therapeutics market in North America during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate rate during the forecast period.

Key trend of new product development and launch in the international market is observed among leading players
The report also provides profiles of the leading players operating in the global Parkinson’s disease therapeutics market.  AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc. are some of the prominent players in the market having proprietary products and technologies. Most of them are focused on new product development, approvals, and commercialization of novel drugs to gain the first-mover’s advantage and address the unmet needs in the Parkinson’s disease therapeutics market. For instance, In January 2015, AbbVie’s flagship product, DUOPA (Combination Drug of carbidopa and levodopa), received the approval of the United States FDA for the treatment of advanced Parkinson’s disease.

Duopa is administered through a unique technology directly into the intestine of the patient through the stoma. It is the first and only kind of product administered through intestinal infusion. In 2016, the ACADIA Pharmaceuticals Inc. launched its antipsychotic drug, Nuplazid, in the U.S. Nuplazid is the first and only drug approved by the United States FDA for the management of hallucination and delusion associated with Parkinson’s disease. Other prominent players operating in the global Parkinson’s disease therapeutics market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

More Trending Reports by Transparency Market Research –  

Oncology Information System Market –

Gonorrhea Therapeutics Market –
Posted by at No comments:

Bacterial Conjunctivitis Drugs Market Overview and Regional Outlook Study

The bacterial conjunctivitis drug market in U.S. is extremely fragmented in nature as various players are operating in the market. According to a report by Transparency Market Research, the players in the market is expecting a fierce rise in competition due to entrance of new players. New players are facing entry barrier because of capital but the capabilities of good research and development facilities are encouraging them to invest in the market. Big pharmaceutical firms and small biotech research organizations are taking part in strategic alliances such as mergers and acquisitions. Players are shifting their focus on developing medicines that are herbal as the consumers are adopting herbal treatment regime over pharmacological medicines.
The leading players operating in the bacterial conjunctivitis market in U.S are Santen Pharmaceutical Co. Ltd., Valeant Pharmaceuticals Int. Inc., Perrigo Com. Plc., Pfizer Inc., Merk & Co. Inc., Novartis AG, Actavis Plc., Bayer AG, Hoffmann-La Roche Ltd., and Akorn Inc.

Request For Covid19 Impact Analysis on Bacterial Conjunctivitis Drugs Market –

According to a report by Transparency Market Research, the U.S bacterial conjuctvitis drugs market is anticipated to attain a valuation of US$ 439.8 mn by the end of forecast period 2024.
The U.S bacterial conjunctivitis drug class is led by topical fluoroquinolones segment however, the demand for this segment is likely to reduce drastically in the coming years owing to patent expiration of the best drugs of this class. The drugs include Zymaxid, Vigamox, and Moxeza. This segment is expected to fall down to US$ 286.4 mn by the end of 2024 due to obtrusion of genetic variation of these drugs.

Shift to Herbal Treatment from Pharmaceutical Medication will Boost the Market
The bacterial conjunctivitis drug market in U.S is shifting to herbal treatment from pharmaceutical medicines. This shift in adoption is majorly due to rise in awareness among consumers. This shift is encouraging manufacturers to develop herbal products for bacterial conjunctivitis treatment to earn profit. The market can witness high profit income due to shift of preference. This infection susceptibility spreads among all age groups from infants to elderly leading to rise in demand for the market. This will likely boost the market in the coming years. Rise in awareness among people about the disease and its treatment is also boosting the market. Several states are actively promoting treatment of the disease. Easy availability of the treatment is boosting the market. Rise in disposable income in the U.S is also fueling the market. These factors are likely to bring positive growth in the U.S market for bacterial conjunctivitis.

Request for Brochure of Report -

Scarcity of Novel Compounds for Clinical Examination is Likely to Hamper Market Growth
The U.S bacterial conjunctivitis market is expected to face certain restrains in the market that might hamper its growth in the coming years. The market is expecting to face a patent cliff in the coming years. The availability of certain cost effective generic medicines is likely to hamper the market growth extensively. The scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of market. Dearth of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline is affecting the market for bacterial conjunctivitis in U.S.

The rise in drug expiry is leading to doctors prescribing variety of generic medicines that are affordable thus, hampering the market growth. Optometrists and ophthalmologists are mainly prescribing antibiotics as ointments and eye drops which is affecting the market growth. Rise in awareness has also made patients aware that the bacterial conjunctivitis is generally acute and cures on its own in few years. These factors are likely to hamper the growth and make it sluggish in the coming years.

More Trending Reports by Transparency Market Research –  
Particle Therapy Market –

Controlled Substance Market –
Posted by at No comments:
Subscribe to: Posts (Atom)